S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.

• Rafael F Duarte,
• Sophie Alain,
• Roy F Chemaly,
• Carmen Montoto,
• Isabel de Castro-Orós,
• Johan Maertens,
• Ignacio Tagarro

Affiliations

Rafael F Duarte

1 Hospital Universitario Puerta de Hierro, Department of Haematology, Majadahonda, Madrid, Spain

Sophie Alain

2 Limoges University Hospital, UMR Inserm 1092, University of Limoges, Department of Virology and National Reference Center for Herpesviruses, Limoges, France

Roy F Chemaly

3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Carmen Montoto

4 Takeda Pharmaceuticals, Medical Department, Madrid, Spain

Isabel de Castro-Orós

4 Takeda Pharmaceuticals, Medical Department, Madrid, Spain

Johan Maertens

5 University Hospitals Leuven, KU Leuven, Haematology Department, Leuven, Belgium

Ignacio Tagarro

4 Takeda Pharmaceuticals, Medical Department, Madrid, Spain